/Quest%20Diagnostics%2C%20Inc_%20logo%20on%20building-by%20Tada%20Images%20via%20Shutterstock.jpg)
Quest Diagnostics has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.
/Henry%20Schein%20Inc_%20sign%20outside%20office-by%20JHVEPhoto%20via%20Shutterstock.jpg)
Henry Schein has trailed the broader market over the past year, yet analysts maintain a cautiously optimistic outlook on its future performance.
/HCA%20Healthcare%20Inc%20sign%20on%20building-by%20JHVEPhoto%20via%20Shutterstock.jpg)
HCA Healthcare has lagged behind the broader market this year, yet analysts maintain a fairly positive outlook on its future performance.
/Cigna%20Group%20HQ%20phone%20-by%20JHVEPhoto%20via%20Shutterstock.jpg)
The Cigna Group observed a notable drop in earnings in the recent quarter and has continued to underperform other healthcare services stocks over the past year. Yet, analysts remain strongly bullish on...
Cardinal Health has observed a notable surge in stock prices recently and received several ratings upgrades shifting the consensus to a "Strong Buy."
/Centene%20Corp_%20logo%20on%20phone-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
Although Centene has lagged behind the broader market over the past year, Wall Street analysts remain moderately optimistic about the stock's growth potential.
Shares have climbed more than 5% since last week's earnings report, with many retail traders arguing the stock is oversold and offers an attractive entry point.
Quest completed eight acquisitions in 2024, including LifeLabs, expanded its advanced diagnostics portfolio, and extended its market reach with new clinical, consumer, and health plan customers.
The company revised its full-year 2025 adjusted EPS to $29.50, below the $31.48 estimate, and projected adjusted revenue of at least $252 billion.
The board approved a new $10 billion share repurchase program, which added to investor optimism.